In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio

In $94M Agreement, Royalty Pharma Acquires Royalty Interest in Entyvio
0
(0)

Royalty Pharma has bought Massachusetts General Hospital’s (MGH) royalty interest in the inflammatory bowel disease (IBD) therapy Entyvio (vedolizumab) for $94 million.

Produced by Millennium Pharmaceuticals, which is part of Takeda, Entyvio is available in more than 60 countries. Sales of the monoclonal antibody exceeded $3 billion last year, a 30% increase over 2018.

By acquiring existing royalty interests from original innovators, Royalty Pharma indirectly funds scientific innovation. The company’s portfolio now includes royalty interests in more than 50 approved products.

“Because of the discoveries of researchers at Massachusetts General Hospital, Entyvio has improved the lives of hundreds of thousands of patients with IBD,” Pablo Legorreta, founder and CEO of Royalty Pharma, said in a press release.

“Through transactions such as this, we are furthering our goal of accelerating innovation and making the life sciences research and development ecosystem more efficient and productive,” Legorreta said.

Robert Colvin, an MGH physician and researcher, made the foundational discovery that led to the development of Entyvio, an every-eight-weeks intravenous treatment for adults with moderate-to-severe ulcerative colitis and Crohn’s disease who fail to respond to other therapies.

“I find it incredibly exciting that a basic scientific discovery made decades ago in a different field has translated into a treatment that is directly helping so many patients today,” Colvin said. “I feel privileged to have been part of the extraordinary pathology team that moved this work forward.”

Approved in 2014 by the U.S. Food and Drug Administration (FDA), the gut-selective maintenance therapy Entyvio works by preventing pro-inflammatory immune cells from accessing the gastrointestinal tract.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recommended approval of subcutaneous (under the skin) Entyvio injections for the treatment of adults with moderate-to-severe ulcerative colitis and Crohn’s disease.

Results from a Phase 3 trial (NCT02611817) showed that, after a year, the treatment’s new formulation as an under-the-skin injection led to more patients entering clinical remission compared to those given a placebo. If approved, this new formulation will allow patients to self-medicate at home instead of going to the hospital to receive the injection.

“The work and dedication of the MGH inventor team of Harvard-appointed pathologists led by Robert Colvin, MD, along with Atul Bhan, MD, James Kurnick, MD, Andrew Lazarovitz, MD, PhD, and Richard Moscicki, MD, is reflective of a system-wide commitment to improving care for patients dealing with challenging conditions,” said Chris Coburn, chief innovation officer at Partners HealthCare.

“Through this transaction with Royalty Pharma, we’ll be able to accelerate our investment in discovery and science for the benefit of patients worldwide. Our congratulations to the remarkable team of pathologists who realized this vision for improving patient care,” Coburn said.

Approximately 1.6 million U.S. residents have IBD, and as many as 70,000 new cases are diagnosed in the country every year, according to the Crohn’s & Colitis Foundation. Ulcerative colitis and Crohn’s are the main forms of IBD.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 30
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • takeda research collaboration
  • CT-SCOUT app studied
  • gut microbes
  • Genedata

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?